product name Salmeterol Xinafoate
Description: Salmeterol Xinafoate is a long-acting β2-adrenergic receptor agonist with anti-inflammatory effects, it is used in the treatment of asthma symptoms and chronic obstructive pulmonary disease (COPD) symptoms. These symptoms include shortness of breath, wheezing, coughing and chest tightness. Salmeterol is also used to prevent breathing difficulties during exercise (exercise induced bronchospasm).
References: Mol Pharmacol. 1998 Oct;54(4):616-22.
603.75
Formula
C36H45NO7
CAS No.
94749-08-3
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 100 mg/mL (165.6 mM)
Water: <1 mg/mL
Ethanol: 4 mg/mL (6.6 mM)
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19397729
| In Vitro |
In vitro activity: In a previoius study, it was found that salmeterol could reduce retinal Müller cell death through the inhibition of the phosphorylation of IRS-1(Ser307). In addition, the findings also suggest the importance of IRS-1 in beta-adrenergic receptor signaling in the prevention of cell death in retinal Müller cells. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | A previous animal study showed that salmeterol significantly decreased the production of pro-inflammatory cytokines in a model of allergen-challenged mice, which expressed tumor-necrosis factor-alpha, interleukin-1 and interleukin-6. Moreover, it was found that salmeterol could reduce the inflammation caused by lipopolysaccharide in activated murine bone marrow-derived dendritic cells (DCs). Therefore, this study suggested that salmeterol regulated the inflammation of allergen-induced asthma by modulating DCs, providing evidence that DCs were the target immune cells responsible for the action of salmeterol against asthma. |
| Animal model | |
| Formulation & Dosage | |
| References | Mol Vis. 2012;18:271-9; Cell Mol Immunol. 2012 May;9(3):267-75. |
Related Posts
product name Salmeterol Xinafoate
Description: Salmeterol Xinafoate is a long-acting β2-adrenergic receptor agonist with anti-inflammatory effects, it is used in the treatment of asthma symptoms and chronic obstructive pulmonary disease (COPD) symptoms. These symptoms include shortness of breath, wheezing, coughing and chest tightness. Salmeterol is also used to prevent breathing difficulties during exercise (exercise induced bronchospasm).
References: Mol Pharmacol. 1998 Oct;54(4):616-22.
603.75
Formula
C36H45NO7
CAS No.
94749-08-3
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 100 mg/mL (165.6 mM)
Water: <1 mg/mL
Ethanol: 4 mg/mL (6.6 mM)
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19397729
| In Vitro |
In vitro activity: In a previoius study, it was found that salmeterol could reduce retinal Müller cell death through the inhibition of the phosphorylation of IRS-1(Ser307). In addition, the findings also suggest the importance of IRS-1 in beta-adrenergic receptor signaling in the prevention of cell death in retinal Müller cells. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | A previous animal study showed that salmeterol significantly decreased the production of pro-inflammatory cytokines in a model of allergen-challenged mice, which expressed tumor-necrosis factor-alpha, interleukin-1 and interleukin-6. Moreover, it was found that salmeterol could reduce the inflammation caused by lipopolysaccharide in activated murine bone marrow-derived dendritic cells (DCs). Therefore, this study suggested that salmeterol regulated the inflammation of allergen-induced asthma by modulating DCs, providing evidence that DCs were the target immune cells responsible for the action of salmeterol against asthma. |
| Animal model | |
| Formulation & Dosage | |
| References | Mol Vis. 2012;18:271-9; Cell Mol Immunol. 2012 May;9(3):267-75. |